(Mesna Sodium 2-mercaptoethanesulphonate)


Each injection contains Mesna Sodium 2-mercaptoethanesulphonate 400mg

ATC Code

V03AF01 — Mesna



Mesna is a detoxifying agent to inhibit the hemorrhagic cystitis induced by ifosfamide. This medication is used to reduce the risk of bleeding in the bladder (hemorrhagic cystitis), which is a very serious side effect of treatment with a cancer chemotherapy drug called ifosfamideMesna helps to protect the lining of the bladder against damage from ifosfamide. The body breaks down ifosfamide to form a product that can harm the bladder, and mesna works by making this product less harmful. However, mesna does not change ifosfamide’s anti-cancer effects.




0.65 ± 0.24 L/kg; distributed to total body water.


Rapidly oxidized to mesna disulfide (dimesna) in the intravascular compartment. Mesna and dimesna do not undergo hepatic metabolism.


Urine (32% as mesna; 33% as dimesna).

Time to Peak

Plasma: Oral: Free mesna: 1.5 to 4 hours; Total mesna: 3 to 7 hours.

Half-Life Elimination

Mesna: ~22 minutes; Dimesna: ~70 minutes.

Protein Binding

69% to 75%.

Mechanism of Action

Mesna belongs to abdominal pain a class of drugs called cytoprotectants. It protects the urinary bladder from harmful effects of ifosfamide and cyclophosphamide.

In blood, mesna is oxidized to dimesna which in turn is reduced in the kidney back to mesna, supplying a free thiol group which binds to and inactivates acrolein, the urotoxic metabolite of ifosfamide and cyclophosphamide

Product Information

Share This Story, Choose Your Platform!